Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017
ReportsWeb.com published “Non Alcoholic Fatty Liver Disease Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this marke
(EMAILWIRE.COM, October 05, 2017 ) ReportsWeb.com published “Non Alcoholic Fatty Liver Disease Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Original Content:
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.
For more information about this report: http://www.reportsweb.com/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2017
Publisher's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001689431/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Companies Mentioned:
Allergan Plc
Arisaph Pharmaceuticals Inc
AstraZeneca Plc
Betagenon AB
Bird Rock Bio Inc
Can-Fite BioPharma Ltd
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc
Corcept Therapeutics Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corp
Enanta Pharmaceuticals Inc
Eternygen GmbH
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Genfit SA
Gilead Sciences Inc
Huons Co Ltd
Immuron Ltd
Kyorin Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Miyarisan Pharmaceutical Company Ltd
NovaTarg Therapeutics Inc
Pfizer Inc
Renova Therapeutics Inc
Sancilio & Company Inc
TaiwanJ Pharmaceuticals Co Ltd
TCM Biotech International Corp
Zydus Cadila Healthcare Ltd
Inquire for Report at http://www.reportsweb.com/buy&RW0001689431/buy/2000
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Original Content:
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.
For more information about this report: http://www.reportsweb.com/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2017
Publisher's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001689431/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Companies Mentioned:
Allergan Plc
Arisaph Pharmaceuticals Inc
AstraZeneca Plc
Betagenon AB
Bird Rock Bio Inc
Can-Fite BioPharma Ltd
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc
Corcept Therapeutics Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corp
Enanta Pharmaceuticals Inc
Eternygen GmbH
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Genfit SA
Gilead Sciences Inc
Huons Co Ltd
Immuron Ltd
Kyorin Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Miyarisan Pharmaceutical Company Ltd
NovaTarg Therapeutics Inc
Pfizer Inc
Renova Therapeutics Inc
Sancilio & Company Inc
TaiwanJ Pharmaceuticals Co Ltd
TCM Biotech International Corp
Zydus Cadila Healthcare Ltd
Inquire for Report at http://www.reportsweb.com/buy&RW0001689431/buy/2000
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results